Healthcare Industry News:  antibiotic 

Biopharmaceuticals Personnel

 News Release - March 4, 2014

Pernix Therapeutics Appoints Vice President of Compliance

HOUSTON--(Healthcare Sales & Marketing Network)--Pernix Therapeutics Holdings, Inc. (PTX), a specialty pharmaceutical company, today announced the appointment of Jessica Oien as Vice President of Compliance.

“As we continue to focus on growing our business in the U.S., it is a key corporate objective to add seasoned executives in critical areas,” said Doug Drysdale, Pernix’s President and Chief Executive Officer. “Jessica is an accomplished executive with a solid track record of executing successful corporate compliance programs. Jessica will be responsible for overseeing Pernix’s global compliance program. She will direct corporate compliance activities, monitor compliance trends, measure the effectiveness of policies and training, share best practices, and manage compliance-related communications.”

Ms. Oien brings to Pernix 15 years of legal and compliance experience in the pharmaceutical industry. Prior to joining Pernix, Ms. Oien held positions as Vice President of Compliance and Legal Affairs at Somaxon Pharmaceuticals, Inc., Senior Director of Legal Affairs at Verus Pharmaceuticals, Inc., and Senior Director of Legal Affairs at Elan Pharmaceuticals, Inc. Ms. Oien began her legal career as an associate in the corporate practice groups at the law firms of Brobeck, Phleger & Harrison from 1999 to 2001, and Milbank, Tweed, Hadley & McCloy from 1997 to 1999. Most recently, Ms. Oien spent the last five years providing legal consulting services to small to mid-size pharmaceutical companies where she helped her clients with various healthcare compliance matters, as well as providing legal support for their research, clinical and commercial activities.

About Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, manufacturing and development of branded pharmaceutical products. The Company markets a portfolio of branded products, including: CEDAX®, an antibiotic for middle ear infections and a number of treatments for cough and cold conditions including ZUTRIPRO®, REZIRA® and VITUZ®. The Company also markets SILENOR, a non-narcotic product for the treatment of insomnia. The Company promotes its branded products to physicians through its Pernix sales force and markets its generic portfolio through its wholly owned subsidiaries, Cypress Pharmaceuticals and Macoven Pharmaceuticals. The Company’s wholly owned subsidiary, Pernix Manufacturing, manufactures and packages products for the pharmaceutical industry in a wide range of dosage forms. Founded in 1996, the Company is based in Houston, TX.

Additional information about Pernix is available on the Company’s website located at

Cautionary Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “expect,” “anticipate,” “believe,” “seek,” “target” or similar expressions are forward-looking statements. Because these statements reflect the Company’s current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors, as more fully described under the caption "Risk Factors" in our Form 10-K, Form 10-Q and Form 8-K filings with the Securities and Exchange Commission and as otherwise enumerated herein or therein, could affect the Company’s future financial results and could cause actual results to differ materially from those expressed in forward-looking statements contained in the Company’s Annual Report on Form 10-K. The forward-looking statements in this press release are qualified by these risk factors. These are factors that, individually or in the aggregate, could cause our actual results to differ materially from expected and historical results. The Company assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

Source: Pernix Therapeutics Holdings

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.

FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.